MoonLake’s phase 3 psoriatic arthritis nanobody shows first all-endpoints improvement

First nanobody to show all clinical endpoints improved in phase 3 psoriatic arthritis trial

MoonLake’s nanobody has demonstrated improvements across all clinical endpoints in phase 3 trials for psoriatic arthritis, marking the first such nanobody to achieve this milestone. This could expand treatment access for over 1.5 million patients who currently have limited therapeutic options.

The significance lies in psoriatic arthritis’s impact on quality of life and the potential for a more accessible treatment. If approved, this could reduce costs and barriers for patients. However, the trial is still in phase 3, so regulatory approval and real-world availability are not yet confirmed. The source material does not provide details on long-term efficacy or exact patient impact, meaning the full benefit for treatment access remains uncertain. The source material provides only this summary, with full details available in the original report.

Source: Fierce Biotech